Holen Sie sich die Stockscreener-App
28.58
1.96%
0.55
Schlusskurs vom Vortag:
$28.03
Offen:
$27.99
24-Stunden-Volumen:
113.98K
Relative Volume:
1.03
Marktkapitalisierung:
$408.69M
Einnahmen:
$138.20M
Nettoeinkommen (Verlust:
$5.52M
KGV:
75.21
EPS:
0.38
Netto-Cashflow:
$9.86M
1W Leistung:
+6.80%
1M Leistung:
+1.56%
6M Leistung:
-26.19%
1J Leistung:
-16.14%
1-Tages-Spanne:
$27.80
$28.69
1-Wochen-Bereich:
$26.84
$28.69
52-Wochen-Spanne:
$26.00
$42.44
Surmodics Inc Stock (SRDX) Company Profile
Firmenname
Surmodics Inc
Sektor
Branche
Telefon
(952) 500-7000
Adresse
9924 W 74TH ST, EDEN PRAIRIE, MN
Vergleichen Sie SRDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SRDX
Surmodics Inc
|
28.58 | 382.65M | 138.20M | 5.52M | 9.86M | 0.38 |
|
ABT
Abbott Laboratories
|
134.80 | 231.82B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
106.04 | 152.18B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
394.21 | 145.57B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
86.44 | 107.07B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
78.00 | 43.22B | 5.54B | 4.18B | 623.10M | 7.00 |
Surmodics Inc Stock (SRDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-07 | Hochstufung | Lake Street | Hold → Buy |
| 2023-06-13 | Hochstufung | Needham | Hold → Buy |
| 2023-02-13 | Herabstufung | Needham | Buy → Hold |
| 2020-07-23 | Hochstufung | Needham | Hold → Buy |
| 2019-12-11 | Herabstufung | Needham | Buy → Hold |
| 2019-11-01 | Herabstufung | Lake Street | Buy → Hold |
| 2019-08-01 | Bestätigt | Needham | Buy |
| 2019-05-02 | Bestätigt | Lake Street | Buy |
| 2019-05-02 | Bestätigt | Needham | Buy |
| 2019-02-21 | Bestätigt | Needham | Buy |
| 2018-05-16 | Bestätigt | Needham | Buy |
| 2018-03-01 | Hochstufung | Sidoti | Neutral → Buy |
| 2018-02-28 | Bestätigt | Lake Street | Buy |
| 2018-02-28 | Eingeleitet | Needham | Buy |
| 2017-07-14 | Eingeleitet | Lake Street | Buy |
| 2016-11-21 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2016-10-06 | Herabstufung | Sidoti | Buy → Neutral |
| 2016-05-03 | Bestätigt | Barrington Research | Outperform |
| 2015-08-06 | Bestätigt | Barrington Research | Outperform |
| 2015-03-27 | Eingeleitet | Dougherty & Company | Buy |
| 2014-02-25 | Eingeleitet | Laidlaw | Buy |
| 2013-08-01 | Hochstufung | Feltl & Co. | Buy → Strong Buy |
| 2012-11-12 | Bestätigt | Barrington Research | Outperform |
Alle ansehen
Surmodics Inc Aktie (SRDX) Neueste Nachrichten
US FTC files amended complaint to block GTCR acquisition of Surmodics - MLex
Surmodics Shares Positive TRANSCEND Trial Results - Medical Product Outsourcing
Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results - ADVFN
Equities Analysts Issue Forecasts for Surmodics Q2 Earnings - Defense World
Legal & General Group Plc Buys 880 Shares of Surmodics, Inc. (NASDAQ:SRDX) - Defense World
Zacks Research Weighs in on Surmodics FY2025 Earnings - Defense World
Are Options Traders Betting on a Big Move in Surmodics Stock? - Yahoo Finance
SRDX Stock Down Following Q2 Earnings Miss, Gross Margin Contracts - TradingView
SurModics: Fiscal Q2 Earnings Snapshot - New Haven Register
Surmodics Reports Q2 2025 Results Amid Acquisition Challenges - TipRanks
SurModics (SRDX) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
SurModics stock touches 52-week low at $26.21 amid market shifts - Investing.com
Surmodics (SRDX) Projects Declining Revenue for Fiscal 2025 | SR - GuruFocus
Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance - BioSpace
Surmodics (SRDX) Projects Declining Revenue for Fiscal 2025 | SRDX Stock News - GuruFocus
Surmodics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
SurModics (SRDX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Surmodics (SRDX) Reports Lower Than Expected Q2 Revenue Amid Ant - GuruFocus
Surmodics Reports Second Quarter of Fiscal Year 2025 Financial R - GuruFocus
SURMODICS INC SEC 10-Q Report - TradingView
Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance | SRDX Stock News - GuruFocus
Surmodics Reports Second Quarter Fiscal 2025 Financial Results - TradingView
A Look at Surmodics's Upcoming Earnings Report - Nasdaq
How To Trade (SRDX) - news.stocktradersdaily.com
Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30 - 01net
Surmodics to Report Second Quarter of Fiscal 2025 Financial Resu - GuruFocus
FTC Expands Lawsuit Against GTCR Over Surmodics Acquisition - MSN
Surmodics' SurVeil DCB Matches IN.PACT Admiral In Efficacy With Lower Drug Dose In Global Trial - Nasdaq
Surmodics (SRDX) Publishes Promising Clinical Trial Results for SurVeil DCB | SRDX Stock News - GuruFocus
Surmodics Announces Publication of TRANSCEND Trial, Highlighting - GuruFocus
Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon - Business Wire
Illinois, Minnesota join FTC challenge against $627M Surmodics buyout - MedTech Dive
Minnesota AG Ellison joins federal lawsuit to stop merger of companies that make medical device coatings - KIMT
Illinois joins FTC suit to block GTCR’s takeover of Surmodics - Crain's Chicago Business
AG Ellison Joins Suit to Block Surmodics Acquisition - Twin Cities Business
Corebridge Financial Inc. Lowers Stock Position in Surmodics, Inc. (NASDAQ:SRDX) - Defense World
(SRDX) Long Term Investment Analysis - news.stocktradersdaily.com
Surmodics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
SRDX Stock Dips Despite the Launch of Pounce XL Thrombectomy System - Yahoo Finance
Surmodics launches Pounce XL for peripheral artery clot removal By Investing.com - Investing.com South Africa
Surmodics launches Pounce XL thrombectomy system - Yahoo Finance
Surmodics launches Pounce XL for peripheral artery clot removal - Investing.com Australia
Revolutionary Blood Clot Treatment: Pounce XL Shows 80% Success Rate in Just 20 Minutes - Stock Titan
Gardner Lewis Asset Management L P Raises Position in Surmodics, Inc. (NASDAQ:SRDX) - MarketBeat
Learn to Evaluate (SRDX) using the Charts - news.stocktradersdaily.com
Finanzdaten der Surmodics Inc-Aktie (SRDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.85%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):